Does age affect how well Cosentyx (secukinumab) works long-term?
Cosentyx’s sustained efficacy in plaque psoriasis does not show clear evidence of age-related differences based on the available long-term efficacy data. Across follow-up periods reported in clinical studies, patients of different ages maintained responses rather than showing a systematic decline solely due to getting older.
What do the long-term psoriasis data say about age groups?
In long-term studies evaluating sustained response, efficacy was maintained over time for patients, and the results did not identify age as a consistent driver of reduced benefit. The key efficacy findings were reported as sustained (rather than progressively weakening) after treatment initiation, with no prominent age-stratified pattern reported in the provided information [1][2].
Are there any hints of age-related differences in safety instead of efficacy?
Even when efficacy is sustained, older age can matter for tolerability in real-world settings because adverse event risk can change with age due to comorbidities and other medications. However, the question here is specifically about efficacy, and the provided evidence focuses on sustained effectiveness rather than showing that aging reduces efficacy [1][2].
Could age still matter outside the reported trial populations?
Age might influence outcomes indirectly if older patients have factors not captured in efficacy analyses (for example, differences in baseline disease severity, concomitant therapies, or overall health). But that would be a real-world consideration rather than an age-dependent loss of drug effect shown in the cited long-term efficacy reporting [1][2].
Bottom line
Based on the long-term clinical reporting available here, age does not appear to be a factor that meaningfully reduces Cosentyx’s sustained efficacy over time [1][2].
Sources:
1. https://www.cosentyx.com/derm/psoriasis/clinical-results
2. https://www.drugs.com/history/cosentyx.html